Impact of Early Conventional Treatment on Adult Bone and Joints in a Murine Model of X-Linked Hypophosphatemia

被引:12
|
作者
Cauliez, Axelle [1 ,2 ,3 ]
Zhukouskaya, Volha V. [1 ,2 ,3 ,4 ,5 ,6 ]
Hilliquin, Stephane [1 ,2 ,3 ,7 ]
Sadoine, Jeremy [1 ,2 ,3 ]
Slimani, Lotfi [1 ,2 ,3 ]
Miceli-Richard, Corinne [7 ]
Briot, Karine [4 ,5 ,6 ,7 ]
Linglart, Agnes [4 ,5 ,6 ,8 ]
Chaussain, Catherine [1 ,2 ,3 ,4 ,5 ,6 ,9 ]
Bardet, Claire [1 ,2 ,3 ]
机构
[1] Univ Paris, Lab Orofacial Pathol Imaging & Biotherapies URP 2, Montrouge, France
[2] Univ Paris, FHU DDS Net, Dent Sch, Montrouge, France
[3] Plateforme Imagerie Vivant PIV, Montrouge, France
[4] Univ Paris Saclay, Univ Evry, INSERM, INTEGRARE,Genethon, Evry, France
[5] Hop Bicetre, Ctr Reference Malad Rares Metabolisme Calcium & P, Plateforme Expertise Malad Rares Paris Saclay, Filiere OSCAR,EndoRare, Le Kremlin Bicetre, France
[6] Hop Bicetre, BOND ERN, Le Kremlin Bicetre, France
[7] Univ Paris, Cochin Hosp, Dept Rheumatol, Paris, France
[8] Univ Paris Saclay, Hop Bicetre, AP HP, INSERM,U1185,Serv Endocrinol & Diabete Enfant,Ser, Le Kremlin Bicetre, France
[9] Bretonneau Hosp, AP HP, Reference Ctr Rare Disorders Calcium & Phosphate, Dent Med Dept,GHN, Paris, France
来源
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2021年 / 8卷
关键词
rickets; osteomalacia; Hyp mice; phosphorus; conventional treatment; XLH; PHEX; fibroblast growth factor 23;
D O I
10.3389/fcell.2020.591417
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
X-linked hypophosphatemia (XLH) is the most common form of genetic rickets. Mainly diagnosed during childhood because of growth retardation and deformities of the lower limbs, the disease affects adults with early enthesopathies and joint structural damage that significantly alter patient quality of life. The conventional treatment, based on phosphorus supplementation and active vitamin D analogs, is commonly administered from early childhood to the end of growth; unfortunately, it does not allow complete recovery from skeletal damage. Despite adequate treatment during childhood, bone and joint complications occur in adults and become a dominant feature in the natural history of the disease. Our previous data showed that the Hyp mouse is a relevant model of XLH for studying early enthesophytes and joint structural damage. Here, we studied the effect of conventional treatment on the development of bone and joint alterations in this mouse model during growth and young adulthood. Mice were supplemented with oral phosphorus and calcitriol injections, following two timelines: (i) from weaning to 3 months of age and (ii) from 2 to 3 months to evaluate the effects of treatment on the development of early enthesophytes and joint alterations, and on changes in bone and joint deformities already present, respectively. We showed that early conventional treatment improved bone microarchitecture, and partially prevented bone and joint complications, but with no noticeable improvement in enthesophytes. In contrast, later administration had limited efficacy in ameliorating bone and joint alterations. Despite the improvement in bone microarchitecture, the conventional treatment, early or late, had no effect on osteoid accumulation. Our data underline the usefulness of the Hyp murine model for preclinical studies on skeletal and extraskeletal lesions. Although the early conventional treatment is important for the improvement of bone microarchitecture, the persistence of osteomalacia implies seeking new therapeutic strategies, in particular anti-FGF23 approach, in order to optimize the treatment of XLH.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Impact of stopping burosumab treatment at the end of skeletal growth in adolescents with X-linked hypophosphatemia (XLH)
    Jarvis, Charlotte
    Ramakrishnan, Renuka
    Dharmaraj, Poonam
    Mushtaq, Talat
    Gupta, Sanjay
    Williams, Angela
    Rylands, Angela J.
    Barham, Helen
    Nixon, Annabel
    Uday, Suma
    BONE REPORTS, 2025, 24
  • [22] Treatment of X-Linked Hypophosphatemia with Calcitriol and Phosphate Increases Circulating Fibroblast Growth Factor 23 Concentrations
    Imel, Erik A.
    DiMeglio, Linda A.
    Hui, Siu L.
    Carpenter, Thomas O.
    Econs, Michael J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (04) : 1846 - 1850
  • [23] Reassuring Data on the Cardiovascular Risk in Adults With X-linked Hypophosphatemia Receiving Conventional Therapy
    Bouzemane, Alexandre
    Vignot, Emmanuelle
    Derain Dubourg, Laurence
    De Mul, Aurelie
    Molin, Arnaud
    Chapurlat, Roland
    Fontanges, Elisabeth
    Delsart, Daphne
    Akbari, Alirea
    Huang, Shih Han Susan
    Mcintyre, Christopher W.
    Bacchetta, Justine
    Lemoine, Sandrine
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (02) : e488 - e494
  • [24] Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-linked hypophosphatemia (XLH)
    Carpenter, Kelsey A.
    Alkhatib, Delia O.
    Dulion, Bryan A.
    Guirado, Elizabeth
    Patel, Shreya
    Chen, Yinghua
    George, Anne
    Ross, Ryan D.
    INTERNATIONAL JOURNAL OF ORAL SCIENCE, 2023, 15 (01)
  • [25] Orthodontic treatment in children and adolescent patients with X-linked hypophosphatemia: A case-control study
    Janssens, Yann
    Duplan, Martin Biosse
    Linglart, Agnes
    Rothenbuhler, Anya
    Chaussain, Catherine
    Le Norcy, Elvire
    ORTHODONTICS & CRANIOFACIAL RESEARCH, 2024, 27 (05) : 697 - 703
  • [26] Meta-analysis and systematic review: burosumab as a promising treatment for children with X-linked hypophosphatemia
    Wang, Kangning
    Zhang, Runze
    Chen, Ziyi
    Bai, Yi
    He, Qing
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [27] Effect of Mutation Type on Ectopic Ossification Among Adult Patients With X-Linked Hypophosphatemia
    Kato, Hajime
    Ishihara, Yasuki
    Ohata, Yasuhisa
    Irie, Koki
    Watanabe, So
    Kimura, Soichiro
    Hoshino, Yoshitomo
    Hidaka, Naoko
    Kinoshita, Yuka
    Taniguchi, Yuki
    Kobayashi, Hiroshi
    Braddock, Demetrios T.
    Kubota, Takuo
    Ozono, Keiichi
    Nangaku, Masaomi
    Makita, Noriko
    Ito, Nobuaki
    JOURNAL OF THE ENDOCRINE SOCIETY, 2024, 8 (12)
  • [28] Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia
    Ward, Leanne M.
    Glorieux, Francis H.
    Whyte, Michael P.
    Munns, Craig F.
    Portale, Anthony A.
    Hoegler, Wolfgang
    Simmons, Jill H.
    Gottesman, Gary S.
    Padidela, Raja
    Namba, Noriyuki
    Cheong, Hae Il
    Nilsson, Ola
    Mao, Meng
    Chen, Angel
    Skrinar, Alison
    Roberts, Mary Scott
    Imel, Erik A.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (08) : E3241 - E3253
  • [29] Effects of Burosumab Treatment on Mineral Metabolism in Children and Adolescents With X-linked Hypophosphatemia
    Ewert, Annika
    Rehberg, Mirko
    Schlingmann, Karl Peter
    Hiort, Olaf
    John-Kroegel, Ulrike
    Metzing, Oliver
    Wuehl, Elke
    Schaefer, Franz
    Kemper, Markus J.
    Derichs, Ute
    Richter-Unruh, Annette
    Patzer, Ludwig
    Albers, Norbert
    Dunstheimer, Desiree
    Haberland, Holger
    Heger, Sabine
    Schroeder, Carmen
    Jorch, Norbert
    Schmid, Elmar
    Staude, Hagen
    Weitz, Marcus
    Freiberg, Clemens
    Leifheit-Nestler, Maren
    Zivicnjak, Miroslav
    Schnabel, Dirk
    Haffner, Dieter
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (10) : E998 - E1006
  • [30] Growth hormone treatment improves final height in children with X-linked hypophosphatemia
    Julia André
    Volha V. Zhukouskaya
    Anne-Sophie Lambert
    Jean-Pierre Salles
    Brigitte Mignot
    Claire Bardet
    Catherine Chaussain
    Anya Rothenbuhler
    Agnès Linglart
    Orphanet Journal of Rare Diseases, 17